Alirocumab - Lipid modification
You are here : Home > Formulary Search > Alirocumab - Lipid modification
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
- Subcutaneous injection (sc)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Restricted to lipidologists only.
Documentation
NICE Technology Appraisal
Evidence Review
PAD Profile
ChemicalSubstance :
Alirocumab
Indication :
Lipid modification
Group Name :
Keywords :
Hyperlipidaemia, PCSK9 inhibitor, lipid regulating, mixed dyslipidaemia, Primary hypercholesterolaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Praluent
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5
Other Indications
Below are listed other indications that Alirocumab is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Lipid modification.
Committee Recommendations (2)
The APC recommends both presentations of alirocumab: 150mg fortnightly (see previous recommendation) AND 300mg monthly (new recommendation).
The monthly 300mg presentation maybe more conveniant for patients. It was not covered in the evidence base underpinning NICE TA393 but the PAS price is the same monthly cost as 150mg fortnightly.
Prescribing of either product should be in line with NICE TA393 under the conditions agreed in October 2016
The PCN recommends alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA393 (June 2016)
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Alirocumab will be considered RED on the traffic light system
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Alirocumab will be considered RED on the traffic light system